Table 4.
Multivariable Analyses of Baseline Variables in Relation to Clinical Outcomes
| Total Mortality | Cardiac Mortality | HF Hospitalization | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | P Value | HR | 95% CI | P Value | HR | 95% CI | P Value | ||||
| Lead type (QUAD) | 0.32 | 0.20 | 0.52 | <0.001 | 0.36 | 0.20 | 0.65 | 0.001 | 0.62 | 0.39 | 0.99 | 0.047 |
| Sex, male | 1.65 | 1.18 | 2.31 | 0.003 | 1.74 | 1.13 | 2.70 | 0.013 | ··· | ··· | ··· | ··· |
| Age, y | 1.03 | 1.02 | 1.05 | <0.001 | 1.02 | 1.00 | 1.03 | 0.043 | 1.03 | 1.01 | 1.05 | 0.001 |
| NYHA class (IV) | 1.89 | 1.25 | 2.86 | 0.003 | ··· | ··· | ··· | ··· | ··· | ··· | ··· | ··· |
| QRS duration, ms | ··· | ··· | ··· | ··· | 0.99 | 0.99 | 1.00 | 0.019 | 0.99 | 0.98 | 0.99 | <0.001 |
| ACEIs/ARAs | ··· | ··· | ··· | ··· | 0.64 | 0.42 | 0.99 | 0.044 | ··· | ··· | ··· | ··· |
| Creatinine, log μmol/L | 1.68 | 1.25 | 2.25 | 0.001 | 1.50 | 1.04 | 2.16 | 0.030 | 1.91 | 1.30 | 2.80 | 0.001 |
Only variables with P<0.10 on univariable analyses were included in multivariable models. ACEI, angiotensin‐converting enzyme inhibitors; ARA, angiotensin receptor blockers; HF, heart failure; NYHA, New York Heart Association; QUAD, quadripolar left ventricular lead.
Results are expressed as hazard ratios and 95% confidence intervals (CI) from Cox proportional hazards analyses.